In its recent ESG report, multinational dialysis firm Diaverum revealed the top 10 countries in Europe and internationally where patients use the group's holiday dialysis treatment.
Swedish multinational dialysis firm Diaverum is being bought by M42, a joint venture between Abu Dhabi sovereign wealth fund Mubadala Investment Co and AI firm G42, for a reported $2bn-$2.5bn. Diaverum’s CEO tells HBI the deal offers further opportunities to develop its digital strategies, and international expansion.
Last week the news broke that Abu Dhabi sovereign wealth fund Mubadala Investment Co might be set to buy Swedish multinational dialysis firm Diaverum for a reported $2.5bn. HBI speaks to an operator source who thinks this would be a good price for the seller - and hears why some investors are switched off by dialysis.
Abu Dhabi sovereign wealth fund Mubadala Investment Co is considering the acquisition of $2.5bn Swedish pan-European dialysis group Diaverum, according to reports.
Last month, thought leaders from private healthcare systems across the globe gathered in Cape Town, South Africa, to network, share their findings, and consider how emerging markets can become more resilient. HBI was there, and these are our key themes and takeaways.
Michael Sen, CEO of multinational healthcare conglomerate Fresenius, finally set out his long-awaited plan for a “Future Fresenius” at the group’s end of year results this week. But is it a radical shake up, or PR puff? HBI investigates why shareholders appear unconvinced.
Michael Sen, the new CEO of multinational health care conglomerate Fresenius, is making preparations to deconsolidate struggling dialysis subsidiary Fresenius Medical Care (FMC). The plans fall short of full divestment and may not be radical enough to appease investors.
Global renal disease specialist Fresenius Medical Care has parted ways with its new CEO just months after announcing her appointment, and scarcely two months after she took up her post. HBI looks at the surprisingly quick turnaround and tries to work out what happened.
The slump in healthcare listed stocks and downward valuations of private businesses are encouraging potential buyers to examine enticing European healthcare enterprises.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
